Rituximab as maintenance therapy for patients with follicular lymphoma (Q24241273)

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III/IV follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Patient benefits of maintenance immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Rituximab plus chemotherapy in follicular and mantle cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Fourth biannual report of the Cochrane Haematological Malignancies Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Safety of rituximab maintenance therapy in follicular lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

Rituximab maintenance therapy in follicular lymphoma comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

7 January 2021

Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group fo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

7 January 2021

Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

7 January 2021

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

7 January 2021

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

7 January 2021

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

7 January 2021

Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

7 January 2021

Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

7 January 2021

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006552.PUB2

7 January 2021